Rexahn Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial And Operational Results

ROCKVILLE, Md., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2017 and provided an update on the Company's clinical development programs.

“We made very good progress with our clinical stage programs in the first half of the year," said Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. “We continue to enroll patients into our Phase IIa studies of RX-3117 in metastatic pancreatic cancer and advanced bladder cancer. We presented preliminary data on the first ten patients in the bladder cancer study at the American Society of Clinical Oncology (ASCO) annual meeting in June.

Back to news